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Novel Nano-biosensors for Life Science Systems and their
Applications in Early, Accurate, and Non-invasive Melanoma and
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Abstract—Melanoma (the 5th and 6th most common cancer in
Caucasian males and females, respectively), is the most severe
form of skin cancer, which is often fatal if recognized in its
advanced stage. Melanoma is the tumor that originates from
melanocytes (the cells that make the pigment melanin), and may
develop from a nevus (commonly named “mole”). Clinically, it
is very difficult to correctly differentiate nevi with atypical
features or dysplastic nevi, and nevi of special sites from
melanoma. Clearly, new, more powerful, less invasive, time
consuming and expensive tools are needed for an early and
accurate detection of melanoma. In order to address this need,
we propose a development of a new set of tools, namely,
carbon-nanotube-based biosensors for the early and accurate
detection of melanoma. Once successful, we will modify and
apply this new technology to early and accurately detect other
types of cancer.
I. INTRODUCTION
Scope of the problem
Nearly 35 years after President Nixon declared war on
cancer, the disease remains a most elusive and destructive
foe. Researchers know much more today than they did three
decades ago about the 200 or more unique diseases known
collectively as cancer. They are beginning to pin down each
of the steps in the complex pathway that causes the body’s
own cells to mutiny and begin multiplying in a way that strays
drastically and disastrously from the norm. But the war is far
from over.
One of the deadly cancers, melanoma, often underestimated
in its danger, is a form of skin cancer. Melanoma incidence
rates are increasing every year. Currently, the melanoma is
the 5th and 6th most common tumor in Caucasian males and
females, respectively. According to the American Cancer
Society, approximately 62,190 men and women (34,260 men
and 27,930 women) were diagnosed with melanoma of the
skin in 2006, and about 7,910 men and women died for
melanoma in the same year.
This is very significant. Yet, many underestimate the
importance of early and accurate detection of this disease,
assuming that the human eye of the dermatology doctor will
catch a problem just in time. However, this is often not the
case. It is often very difficult to correctly diagnose a
melanoma and differentiate it from an indolent nevus lesion
that would never acquire malignant potential. Thus,
unnecessary surgeries, which are both expensive and
traumatic, are often conducted to avoid missing a potential
deadly form of cancer.
A large epidemiological study published a few years ago in
JAMA, aimed at quantifying melanoma risk associated with
nevi, found that risk for melanoma was strongly related to
number of small nevi, large non-dysplastic nevi, and
clinically dysplastic nevi. In the absence of dysplastic nevi,
increased numbers of small nevi was associated with an
approximately 2-fold risk, and increased numbers of both
small and large non-dysplastic nevi was associated with a
4-fold risk. One clinically dysplastic nevus was associated
with a 2-fold risk (95% confidence interval, 1.4-3.6), while
10 or more conferred a 12-fold increased risk (95%
confidence interval, 4.4-31)1. Interestingly, similar results
were observed in Mediterranean populations, typically
considered at lower risk of melanoma, suggesting that these
risk factors are important across geographical regions2. Nevi
and dysplastic nevi are common in Caucasians, particularly in
melanoma-prone families, where it is not infrequent to detect
hundreds of nevi per person.
The most difficult problem
The biggest problem is the difficulty in detecting a nevus
with malignant potential…
The sequential progression model for melanocytic tumors
from common nevus to malignant melanoma was proposed
by Clark almost 30 years ago. The "dysplastic nevus" has
frequently been considered a logical offspring of this concept
and as a direct precursor of melanoma, analogous to the
epithelia - dysplasia - carcinoma sequence. Despite the use of
modern molecular methods, there is no consensus as to if the
dysplastic nevus represents a true precursor lesion of
melanoma, a separate distinct type of nevus, or a diagnostic
dilemma.
Currently, the concept of melanocytic dysplasia remains
subject to confusing definitions at all levels of the diagnostic
process, i.e. clinical appearance, dermatohistopathology, and
molecular biology. Nevi fulfilling Clark and Elder' sclassic
histological criteria mostly represent "endpoints" of
nevocytic evolution, whereas a minority of “dysplastic nevi”
represents true melanoma precursors3. The unsolved dilemma
is that neither clinical, histopathological nor molecular or
dermatoscopy criteria exist to make a distinction between
dysplastic nevi and early melanomas.
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A relatively common, recently recognized, and growing
group of nevi may simulate both dysplastic nevi and
melanomas. These lesions have been termed, generically,
' nevi of special sites' . These lesions may show architectural
features overlapping with melanomas and may be over
diagnosed as such. If not interpreted as a melanoma, they may
be classified as dysplastic nevi. However, many of these
lesions appear to be isolated phenomena, not associated with
measurably increased melanoma risk. At the same time,
authentic dysplastic nevi may occur in these same ' special
sites' . It is just as important to recognize trulydysplastic nevi
as such, as it is to avoid over diagnosis of nevi of special sites
as dysplastic nevi, or as melanomas. In addition to dysplastic
nevi and nevi of special sites, other skin lesions, such as Spitz
nevi, may resemble melanoma. Moreover, melanoma may
develop in areas not frequently examined, such as the vagina,
or develop without typical melanin component (acromic
melanomas) making the diagnosis of such disease very
challenging even to an expert and skilled dermatologist.
II. PROPOSED POTENTIAL SOLUTIONS
In order to address this need, we propose a development
of a new set of tools, namely, carbon-nanotube-based
biosensors for the early and accurate detection of the
melanoma.
Recently, we have witnessed significant interest in
biological and medical applications of novel inorganic
nano-materials such as nanowires and nanotubes for creation
of new types of analytical tools for biotechnology, life
sciences and medical diagnostics. Planar semiconductors can
serve as the basis for chemical and biological sensors in
which detection can be monitored electrically and/or
optically. For example, a planar field effect transistor (FET)
can be configured as a sensor by modifying the gate oxide
(without gate electrode) with molecular receptors or a
selective membrane for the analyte of interest; binding of a
charged species then results in depletion or accumulation of
carriers within the transistor structure. An attractive feature of
such chemically sensitive FETs is that binding can be
monitored by a direct change in conductance or related
electrical property, although the sensitivity and potential for
integration are limited. The physical properties limiting
sensor devices fabricated in planar semiconductors can be
readily overcome by exploiting nano-scale FETs. Such FETs
have now been realized from both carbon nanotubes4,5 and
semiconductor nanowires (for a recent review see ref. 6).
Indeed, their unique properties have generated a wealth of
research on nano-electronic devices and nanosensors. First,
binding to the surface of a nanowire (NW) or nanotube (NT)
can lead to depletion or accumulation of carriers in the “bulk”
of the nanometer diameter structure (versus only the surface
region of a planar device) and increase sensitivity to the point
that single-molecule detection is possible. Second, the small
size of NW and NT building blocks and recent advances in
assembly indicates that dense arrays of sensors could be
prepared.
Because semiconducting SWNTs have a very high
mobility and all their atoms are located at the surface, they are
the ideal material for ultra small sensors. Kong et al.7 were the
first to build a SWNT chemical sensor for the detection of
NO2 and NH3 gas. Calculations suggested that direct binding
of electron withdrawing NO2 or electron-donating NH3 gas
molecules to the NT surface chemically gated these devices.
Following this initial success, many research groups started
to construct SWNT chemical and biological nanosensors8-15.
Recently, our group at Caltech has developed nanotube
sensors incorporated into microfluidic channels to detect
ionic and fluidic transport16. An individual nanotube is
operated as an electrochemically gated transistor, as shown in
Fig. 1. Establishing a changing fluid flow rate shifts the
transistor threshold by an amount proportional to the flow
rate because of the induced streaming potential. This setup is
readily adapted for the proposed cancer detection
experiments, with the addition of suitable chemical
functionalization of the oxide or the nanotube itself. The
docking of the analyte with the complementary target will
alter the charge environment around the nanotube and shift
the transistor threshold, enabling detection of the chosen
markers (schematic diagram shown in Fig. 2).
Indeed, such a setup based on nanotubes or nanowires has
already been recognized as a very promising system for
biosensors. In a first step, Chen et al.13 immobilized proteins
on the sidewall of carbon nanotubes through a linking
molecule, but they did not report the electrical characteristics.
Proteins carry pH-dependent charged groups that can
electrostatically gate a semiconducting SWNT, creating the
possibility to construct a nano-size protein and/or pH sensor.
Even more interesting, redox enzymes go through a catalytic
reaction cycle where groups in the enzyme temporarily
change their charge state and conformational changes occur
in the enzyme. This enzymatic activity can potentially be
monitored with a nanotube sensor.
V
VCE SiO2
I
PDMS channel
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Fig. 1: Experimental setup for nanotube flow sensor. An ionic solution is
passed through a microfluidic channel that has an integrated individual
single-walled nanotube transistor. The voltage VCE applied to the
counter-electrode acts as a gate voltage, and the conductance is measured
through the attached source and drain electrodes.
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Fig. 2. Schematic of nanosensor field-effect transistor (FET) based on
nanowire or nanotube (shown in red).
Nanotubes have potentially an advantage over the
nanowires, since they have a diameter that is 1 order of
magnitude smaller than the nanowires, therefore there might
be an increased sensitivity to be discovered in detecting small
molecules. In addition, their surface is directly exposed to the
environment, circumventing any issues that may arise from
the presence of a surface oxide. In our work, we plan to use
the network nanotube array devices (NTNFETs), among
other nanotube-based sensors, to be most effective in this
investigation as label free detection devices. An electron
microscope image of a NTNFET is shown in Fig. 3, taken
from the work of Alexander Star, et al.15 Label-free detection
has several advantages including cost, time, and simplicity.
Hand-held field-ready devices as opposed to laboratory
methods using labor-intensive labeling and sophisticated
optical equipment will be enabled by this approach.
III. SECONDARY AIM
Since it is necessary to sense a set of cancer markers for
melanoma simultaneously, we need to design a sensing
platform for detection of a set of well-established cancer
markers used and proposed to be used for diagnosis now.
These include MART-1 (MelanA). This antibody stains all
melanocytes, benign and malignant. It is helpful in
diagnosing melanoma in situ vs. a dysplastic nevus; and
Ki-67, a proliferation marker. Other newly proposed markers
of invasiveness and metastatic dissemination of melanoma
will be also tested, not only for early detection of melanoma,
but potentially also for prognosis. Examples of additional
markers that could be tested are listed in Table 1. 17
Fig. 3. Scanning electron microscope image of a nanotube network FET. The
distance between the source (S) and drain (D) electrodes is 10 m. Image
taken from ref. 15.
Marker Correlation
with tumor
thickness
Correlation
with
pathological
stages
Correlation
with
survival
Independent
prognostic
marker
p-AKT × × ×
Ephrin A1 × ×
Apaf-1 ×
Bcl-2 × × ×
-Catenin × × ×
CEACAM1 × × ×
P-cadherin × × ×
CXCR4 × × × ×
Cox-2 ×
Ets-1 × – –
HIF × ×
MITF × ×
MTAP × ×
Pleiotrophi
n
× ×
PLK-1 × ×
PUMA × ×
SOCS × ×
Wnts ×
Table 1 Examples of additional markers that could be tested.
To meet this objective, we shall design and fabricate
NTNFET devices as micro-arrays for high-throughput
function determination. We will develop miniaturized assays
that accommodate extremely low samples volumes and
enable the label-free, rapid, simultaneous processing of vast
number of proteins (cancer markers). Because electronic
measurement using NTNFET devices involves molecular
interactions between protein or DNA molecules and
sidewalls of carbon nanotubes, carbon nanotubes themselves
function as labels. As a first step we shall try to bind
melanoma cancer marker Ki-67 – monoclonal antibody to the
oxide surface near the nanotube (later other ones will also be
tried). We will use Schiff’s base linkage chemistry to
immobilize the monoclonal antibodies on the silica substrate
(see e.g. ref. 18).
Next, we shall address the secondary aim, by multiplexing
and detecting several melanoma cancer markers, which will
be suggested by our pathologist. Finally, we shall proceed
with future aims, including a design and fabrication of a lab
on the chip and hand-held device for an early, accurate, and
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very sensitive detection of melanoma and possibly other
types of cancer.
IV. FUTURE AIMS
Why lab on the chip, for complete diagnostics of
melanoma cancer markers in vivo, as a hand-held device for
clinical studies? Currently, typical diagnosis is carried out
starting with the visit to the dermatologist and his/her eye
exam of the skin, possible biopsy, and photographs of the
nevi that are followed up in time. In order to diagnose
properly, the excision is necessary and it may vary in size, the
extent of surgery and overall caused trauma to the patient.
The diagnosis may take up to a month long and the markers
used to stain the nevi are generally recognized through
reading under microscope. If the cancer has already spread
throughout the body, it may be too late to treat it in a timely
fashion. On the other hand, there is only that much skin that
can be excised. For patients from families prone to
melanoma, it is virtually impossible to remove or suspect
nevi. In addition, many of the removed nevi are examined and
diagnosed not to be cancerous. Therefore, we have many
unnecessary surgeries and patient’s trauma plus significant
cost of the operation. This is why new methods for fast,
non-invasive, and accurate diagnosis in vivo are necessary.
We plan to place our sensing platform on the chip, in near
future, with additional electronics and photonics parts for in
vivo imaging/visualization capabilities. We envision this tool
to be a hand-held device that would replace the current
clinical diagnostic methods by giving us fast and accurate
response on change of electrical conductance, as the specific
cancer marker detection, and visualization of the affected
area at very high resolution. Once successfully tested in
clinical trials, these tools could be applied to detect other
types of cancer.
V. ADVANTAGES OF A PROPOSED METHOD OVER
CURRENT DIAGNOSTIC METHODS
Clearly, the advantages are many and very critical for the
survival rate of patients potentially diagnosed with
melanoma. This project, as the first ever launched in this area,
would open many avenues to alternative diagnostic methods
for detecting melanoma almost instantly in a non-evasive
fashion. This would help the public to save time, money,
unnecessary trauma connected with surgery, a long wait-time
for results, costly surgery expenses, and most importantly, to
save their lives.
VI. CONCLUSIONS
Since this an innovative start-up study in this area, we
believe that the advantages of the anticipated results and
further research would lead to break-through tools for fast,
accurate, and inexpensive in-vivo diagnosis of melanoma,
and other cancers, saving thousands of lives every year.
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